Epclusa is a brand-name prescription medication that’s used to treat hepatitis C virus (HCV) in adults. Bevat per tablet: sofosbuvir 400 mg en velpatasvir 100 mg. Uitleg symbolen.

Open-label trial in GT 2 subjects (N=266). -Patients should be started at lower doses, and the doses should be gradually increased. Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with EPCLUSA Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Epclusa is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2) and Clinical Studies (14)]: 1. without cirrhosis or with compensated cirrhosis 2. with decompensated cirrhosis for use in combination with ribavirin. When administered with EPCLUSA, the recommended dosage of ribavirin is based on weight (administered with food): 1,000 mg per day for patients less than 75 kg and 1,200 … Subjects received EPCLUSA or SOF + RBV for 12 weeks. Recommended Dosage in Adults The recommended dosage of EPCLUSA in adults is one tablet (400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily with or without food [see Clinical Pharmacology (12.3)]. Epclusa rated 8.1/10 vs Harvoni rated 8.6/10 in overall patient satisfaction. Epclusa treats specific genotypes of hepatitis C, and only in certain people.

It is sometimes given in combination with another antiviral medicine called ribavirin in people who also have advanced cirrhosis. Dosage Modifications. EPCLUSA™ sofosbuvir/velpatasvir PARTI: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form/Strength Clinically Relevant Non-medicinal Ingredients oral tablet 400mgsofosbuvir/100 mg velpatasvir Not applicable For a complete listing, see the DOSAGE FORMS, COMPOSITIONAND PACKAGINGsection. Epclusa contains two drugs in one tablet: velpatasvir and sofosbuvir.
Compare Epclusa vs Harvoni head-to-head with other drugs for uses, ratings, cost, side effects, interactions and more. Renal impairment. Table 1 shows the recommended treatment regimen and duration based on patient populationFor patients with HCV/HIV-1 coinfection, follow the dosage recommendations in Table 1 Table 1 Recommended Treatment Regimen and Duration in Patients 6 Years of Age and Older or Weighing at Least 17 kg with Genotype 1, 2, 3, 4, 5, or 6 HCVThe recommended dosage of EPCLUSA in adults is one tablet (400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily with or without food When administered with EPCLUSA, the recommended dosage of ribavirin is based on weight (administered with food): 1,000 mg per day for patients less than 75 kg and 1,200 mg for those weighing at least 75 kg, divided and administered twice daily. Applies to the following strengths: 10 mg; 25 mg; 10 mg/5 mL; 50 mg; 75 mgAlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. 25 mg orally 3 to 4 times per day -Maximum dose: 150 mg/day Comments: -The total daily dosage may be given once a day. Table 3 provides the weight-based dosage of ribavirin when used in combination with EPCLUSA for pediatric patients. 1. Why Are Dementia Patients Getting Risky Psychiatric Drugs? For ribavirin dosage modifications refer to the ribavirin prescribing information The recommended dosage of EPCLUSA in pediatric patients 6 years of age and older or weighing at least 17 kg is based on weight and provided in Table 2. GT 1, 2, 4, or 6 subjects were randomized 5:1 to receive EPCLUSA or placebo for 12 weeks; GT 5 subjects received EPCLUSA for 12 weeks.

-When doses above 100 mg per day are given, plasma levels should be monitored and maintained in the optimum range of 50 to 150 ng/mL. XGVS: Dit geneesmiddel is niet opgenomen in het geneesmiddelen vergoedings systeem (GVS). Epclusa Aanvullende monitoring Gilead Sciences bv. Toedieningsvorm Tablet, omhuld. Epclusa is used to treat chronic hepatitis C in adults and children 6 years of age and older or weighing at least 17kg (37 lbs). Select one or more newsletters to continue. ASTRAL-2. We comply with the HONcode standard for trustworthy health information - Available for Android and iOS devices.

Administer EPCLUSA with or without ribavirin according to the recommendations in Table 1 We comply with the HONcode standard for trustworthy health information - The starting dosage and on-treatment dosage of ribavirin can be decreased based on hemoglobin and creatinine clearance. Double-blind, placebo-controlled trial in GT 1, 2, 4, 5, or 6 subjects (N=740). ASTRAL-3 Take EPCLUSA once daily with or without food Table 2 Dosing for Pediatric Patients 6 Years and Older or Weighing at Least 17 kg with Genotype 1, 2, 3, 4, 5, or 6 HCVTable 3 Recommended Dosing for Ribavirin in Combination Therapy with EPCLUSA for Pediatric Patients 6 Years and OlderNo dosage adjustment of EPCLUSA is recommended in patients with any degree of renal impairment, including patients requiring dialysis.
1. Refer to ribavirin prescribing information for dosage modifications.